semaglutide for ckd Mechanistic effects of on kidney disease in type 2 diabetes: The REMODEL trial" by Katherine Tuttle et al, was awarded with ISNWCN Preserving Kidney Health: Top Scored Abstract. Visual abstract by FDA approves Ozempic to reduce

Lighter belly, healthier gut

Explore treatments for weight loss, sexual health, and hair regrowth, all tailored to your needs.

New study examines how the GLP-1 peptide semaglutide was associated with alcohol-related outcomes in adults with obesity and alcohol use disorder.

Each capsule is formulated to boost energy, focus, metabolism, and suppress appetite for the ultimate weight loss

Subcutaneous semaglutide 2.4 mg injection is a glucagon-like peptide-1 (GLP-1) analogue approved by the European Medicines Agency as an adjunct to a reduced calorie diet and increased physical activity (diet and exercise, D&E) for the treatment obesity and overweight in the presence of at least one weight related comorbidity